

FOI 3770

Gastroenterology New Patients

How many new patients were treated by the Trusts Gastroenterology Department in the latest 3-month period of November, December and January (or the latest 3 months available) with the treatments provided below?

If you are able to, provide the split of new patients who received their treatment for Crohn's disease and Ulcerative colitis? I have provided a table below. Some treatments can only be used for one condition, which I have blocked out.

Define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st November 2025, they are not classed as a new patient for the purposes of this question.

	Total Gastroenterology Department	Crohn's Disease	Ulcerative Colitis
Adalimumab [Humira]	0	0	0
Adalimumab [All Biosimilar]	11	11	0
Etrasimod	0		0
Filgotinib	1		1
Golimumab	0	0	0
Guselkumab	3	3	0
Infliximab [Remicade]	0	0	0
Infliximab [All Biosimilar]	5	1	4
Mirikizumab	3	1	2
Ozanimod	1		1
Risankizumab	4	3	1
Tofacitinib	0		0
Upadacitinib	13	2	11
Ustekinumab [Stelara]	0	0	0
Ustekinumab [All Biosimilar]	16	13	3
Vedolizumab	4	1	3